Navigation Links
ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors
Date:6/8/2009

EXTON, Pa., June 8 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the appointment of Frank Baldino, Jr., Ph.D. to its board of directors.

Dr. Baldino brings several decades of pharmaceutical and health care industry experience and leadership to ViroPharma. He is the chief executive officer and chairman of the board of directors of Cephalon Inc., an international biopharmaceutical company in Chester County, Pennsylvania. Dr. Baldino founded Cephalon in 1987 and has served as chief executive officer and director since its inception.

Prior to joining Cephalon, he served as senior research biologist in the medical products department at E.I. duPont de Nemours & Company, where he was responsible for developing research strategies for identifying novel neuropharmaceutical agents. He has authored more than 100 publications in peer-reviewed journals such as Nature, Journal of Neuroscience Research, and Brain Research. Dr. Baldino received his Ph.D. in pharmacology from Temple University.

Dr. Baldino previously served as a member of ViroPharma's board of directors from 1996 to 2006.

"We are extremely pleased to welcome Frank Baldino, one of the most successful biopharmaceutical entrepreneurs, back to our board of directors," commented Vincent Milano, president and chief executive officer of ViroPharma. "For over a decade, Frank was an extraordinarily valuable member of our board, and we benefited significantly from his guidance and his experience. He brings to ViroPharma a wealth of experience in virtually any issue that a growing pharmaceutical company might encounter, and we are thrilled to welcome him back to our board."

"I am excited to have the opportunity to serve again on the board of directors of ViroPharma; I am proud of the success that the company has achieved and look forward to helping guide the company to its next level of growth and achievement," commented Dr. Baldino.

Dr. Baldino chairs the Executive Council of the Harvard Division of Sleep Medicine and is a member of the Board of Trustees at Temple University and The Franklin (formerly known as The Franklin Institute). In addition, he serves as a member of the Board of Directors for the Greater Philadelphia Chamber of Commerce, the Eastern Technology Council, BioAdvance Biotechnology Greenhouse Corp., Quaker BioVentures, L.P., and Pennsylvania BIO. Dr. Baldino is also a member of the Board of Directors for NicOx, S.A., and Acusphere, Inc.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. ViroPharma commercializes Cinryze(TM) (C1 esterase inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products
2. ViroPharma to Present at Two May Healthcare Conferences
3. ViroPharma to Present at the Cowen & Company 29th Annual Healthcare Conference
4. ViroPharma to Host Investor Teach-In Educational Symposium on Hereditary Angioedema
5. ViroPharma to Release 2008 Fourth Quarter and Full Year Financial Results on February 24, 2009
6. ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
7. ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
8. ViroPharma Provides Update on Vancocin(R)
9. ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema
10. ViroPharma To Present At The 20th Annual Piper Jaffray Healthcare Conference
11. ViroPharma to Discuss Commercialization and Launch of Cinryze(TM) on November 5, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... ... , ... The American College of Medical Informatics (ACMI) will present the 2017 ... Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is ... pioneer in the field of medical informatics, this prestigious award is presented to an ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader ... a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were ... 11, 2017. , The annual award competition recognizes editorial and design excellence across a ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... the nation's first interactive health literacy software tool, and the Cancer Patient Education ... of cancer patient education, today announce a new strategic alliance. , As ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
(Date:9/22/2017)... 2017  As the latest Obamacare repeal effort moves ... (R-LA) and Lindsey Graham (R-SC) medical ... device industry is in an odd place.  The industry ... excise tax on medical device sales passed along with ... patients, increased visits and hospital customers with the funding ...
(Date:9/19/2017)... Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, ... tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , PhD, ...
Breaking Medicine Technology: